What's new

Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 18, Status: Authorised

Mar 27, 2025 - 17:01
 0
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 18, Status: Authorised
Read More

Tags:

Previous Article

GSK tip claiming Pfizer delayed COVID vaccine results during 2020 election promp...

Next Article

HHS to reduce workforce by 20K jobs in major agency-wide restructure

Related Posts

Veterinary medicines European public assessment report (EPAR): Hepizovac, epizootic haemorrhagic disease vaccine (inactivated), Status: Opinion

Veterinary medicines European public assessment report ...

Mar 14, 2025  0

Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/06/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Date of authorisation: 14/10/1998, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0